🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis

Recruitingn/aAges 0 Years - 18 YearsAllInsel Gruppe AG, University Hospital Bern
NCT04026360 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Infants with a confirmed diagnosis of CF by NBS * Age \<=18 years * Written informed consent by patient and/or parent Exclusion Criteria: * Need for respiratory support for more than three days * Severe malformations or known diseases other than CF * Maternal drug abuse * Known severe maternal disease * Severe Problems of communication * Pacemaker, continuous glucose monitor
💊

What it tests

  • no intervention
📍

Where

1 site
University Children's Hospital Bern
Bern, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy